W. Cao

发表

Non-Invasive Biomarkers for Early Detection of Breast Cancer

Z. Fan, L. Ching, Xiaojia Wang, 2020, Cancers.

Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study

Yongmei Yin, Hao Wu, Xiang Huang, 2019, Cancer medicine.

CDH1 germline mutations in a Chinese cohort with hereditary diffuse gastric cancer

Xiaohong Xu, C. Luo, W. Cao, 2021, Journal of Cancer Research and Clinical Oncology.

Serum biomarker 3144 m/z for prognostic detection in Chinese postmenopausal breast cancer patients.

Shenhua Xu, Xiaojia Wang, W. Cao, 2015, Journal of cancer research and therapeutics.

Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study

Xiaojia Wang, Ping Huang, Jun-qing Chen, 2021, Annals of translational medicine.

BRCA1 Germ‐Line Mutations and Tumor Characteristics in Eastern Chinese Women with Familial Breast Cancer

Jicheng Li, Xiaojia Wang, W. Cao, 2013, Anatomical record.

Variants of DNA mismatch repair genes derived from 33,998 Chinese individuals with and without cancer reveal their highly ethnic-specific nature.

S. Wang, H. Lynch, Zixin Qin, 2019, European journal of cancer.

Germline mutations of DICER1 in Chinese women with BRCA1/BRCA2-negative familial breast cancer.

Y. Gao, J. Huang, W. Cao, 2014, Genetics and molecular research : GMR.

BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis

Xiaojia Wang, W. Cao, L. Lei, 2021, Journal of breast cancer.

Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy

H. Jin, Ping Huang, Yuan Huang, 2022, Frontiers in Pharmacology.

Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling

Xue Wu, Y. Shao, Xiaojia Wang, 2019, Molecular genetics & genomic medicine.

Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden

Xiaojia Wang, Tianhui Chen, W. Cao, 2021, Frontiers in Oncology.

Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers

Ting Li, Jie Sun, Jianxia Liu, 2021, Frontiers in Oncology.

Hereditary Breast Cancer in the Han Chinese Population

Jicheng Li, Xiaojia Wang, W. Cao, 2013, Journal of epidemiology.

Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse

Z. Qian, Xiaojia Wang, Yue Hu, 2019, Breast Cancer Research and Treatment.

Differences in the clinicopathological characteristics of pure and mixed invasive micropapillary breast carcinomas from eastern China

Hong Zhang, Xiaojia Wang, A. Lizaso, 2021, Annals of translational medicine.

BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers

Yuntao Xie, L. Hu, Ye Xu, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer

W. Cao, Yun Gao, Xiao-Wen Ding, 2016, BMC Cancer.

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment

I. Ellis, A. Green, E. Rakha, 2019, British Journal of Cancer.

Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients

W. Cao, Haitao Wang, Jiadong Pan, 2022, Journal of Cancer.

Deleterious Mutations in DNA Repair Gene FANCC Exist in BRCA1/2-Negative Chinese Familial Breast and/or Ovarian Cancer Patients

Xiaojia Wang, Tianhui Chen, Yuan Huang, 2019, Front. Oncol..

High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer

Z. Qian, Xiaojia Wang, W. Cao, 2021, Breast Cancer.

Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer: A randomized, controlled, open-label phase II study.

Xiaojia Wang, Yuan Huang, W. Cao, 2022, Journal of Clinical Oncology.

Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China

H. Liang, Xiaojia Wang, Yongsheng Wang, 2022, Frontiers in Oncology.

Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer

Xiaojia Wang, W. Cao, Hongjian Yang, 2016, BMC Cancer.

Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women

G. Peng, Xiaojia Wang, Yuan Huang, 2019, BMC Cancer.

Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer

Jianguo Feng, Yuan Huang, W. Cao, 2023, NPJ breast cancer.

The progress in our understanding of CIN in breast cancer research

W. Cao, Y. Liao, 2023, Frontiers in Oncology.

Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure

Xiaojia Wang, Ping Huang, Jun-qing Chen, 2020, Medicine.

Metastases to the thyroid gland: A retrospective analysis of 21 patients

Yuan Huang, W. Cao, Xiaojian Wang, 2018, Journal of Cancer Research and Therapeutics.

Exploring the concepts and practices of advanced breast cancer treatment: a narrative review

Xiaojia Wang, Yuan Huang, W. Cao, 2021, Annals of translational medicine.

Abstract PS13-01: Primary analysis of OVERSTEP: A multicenter, randomized clinical trial of capecitabine or endocrine therapy as a maintenance therapy after the 1st-line chemotherapy in hormone receptor positive and HER2-negative advanced/metastatic breast cancer

Yongmei Yin, L. Cai, P. Shen, 2021 .

Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study

Xiaojia Wang, W. Cao, X. Shao, 2021, Annals of translational medicine.

Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women

G. Peng, Xiaojia Wang, Yuan Huang, 2019, BMC Cancer.

Identification of Serum Protein Markers for Breast Cancer Relapse With SELDI‐TOF MS

Xiaojia Wang, Hongyang Lu, W. Cao, 2011, Anatomical record.

A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer.

Yi Zhu, W. Cao, Xiao-Wen Ding, 2023, Journal of cancer research and clinical oncology.